These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 32204737)

  • 21. Long-acting injectable antipsychotic (LAI) prescribing trends during COVID-19 restrictions in Canada: a retrospective observational study.
    McKee KA; Crocker CE; Tibbo PG
    BMC Psychiatry; 2021 Dec; 21(1):633. PubMed ID: 34930204
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia.
    Smith RC; Segman RH; Golcer-Dubner T; Pavlov V; Lerer B
    Pharmacogenomics J; 2008 Jun; 8(3):228-36. PubMed ID: 17726453
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complement 3 and metabolic syndrome induced by clozapine: a cross-sectional study and retrospective cohort analysis.
    Zhang C; Zhang Y; Cai J; Chen M; Song L
    Pharmacogenomics J; 2017 Jan; 17(1):92-97. PubMed ID: 26503818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of the metabolic syndrome in Danish psychiatric outpatients treated with antipsychotics.
    Krane-Gartiser K; Breum L; Glümrr C; Linneberg A; Madsen M; Køster A; Jepsen PW; Fink-Jensen A
    Nord J Psychiatry; 2011 Oct; 65(5):345-52. PubMed ID: 21428861
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic predictors for mortality among patients treated with long-term clozapine - A longitudinal study.
    Taub S; Hoshen M; Balicer R; Kamhi-Nesher S; Weizman A; Krivoy A
    Eur Neuropsychopharmacol; 2020 Dec; 41():63-69. PubMed ID: 32981820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic Syndrome and Cardiovascular Risk in People Treated with Long-Acting Injectable Antipsychotics.
    Sanchez-Martinez V; Romero-Rubio D; Abad-Perez MJ; Descalzo-Cabades MA; Alonso-Gutierrez S; Salazar-Fraile J; Montagud V; Facila L
    Endocr Metab Immune Disord Drug Targets; 2018; 18(4):379-387. PubMed ID: 29165095
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics.
    Hägg S; Söderberg S; Ahrén B; Olsson T; Mjörndal T
    J Clin Psychiatry; 2001 Nov; 62(11):843-8. PubMed ID: 11775042
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic syndrome in schizophrenia: a comparative study of antipsychotic-free/naïve and antipsychotic-treated patients from India.
    Pallava A; Chadda RK; Sood M; Lakshmy R
    Nord J Psychiatry; 2012 Jun; 66(3):215-21. PubMed ID: 22017264
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence and predictors of metabolic syndrome among patients attending an outpatient clozapine clinic in Australia.
    Brunero S; Lamont S; Fairbrother G
    Arch Psychiatr Nurs; 2009 Jun; 23(3):261-8. PubMed ID: 19446781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of the metabolic syndrome among patients receiving clozapine.
    Lamberti JS; Olson D; Crilly JF; Olivares T; Williams GC; Tu X; Tang W; Wiener K; Dvorin S; Dietz MB
    Am J Psychiatry; 2006 Jul; 163(7):1273-6. PubMed ID: 16816234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The prevalence of metabolic syndrome and its association with alanine aminotransferase in clozapine-treated Korean patients with schizophrenia.
    Lee NY; Roh MS; Kim SH; Jung DC; Yu HY; Sung KH; Chung IW; Youn T; Kang UG; Ahn YM; Kim YS
    Int Clin Psychopharmacol; 2013 Mar; 28(2):71-9. PubMed ID: 23211493
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A systematic review and meta-analysis of randomised controlled trials of treatments for clozapine-induced obesity and metabolic syndrome.
    Zimbron J; Khandaker GM; Toschi C; Jones PB; Fernandez-Egea E
    Eur Neuropsychopharmacol; 2016 Sep; 26(9):1353-1365. PubMed ID: 27496573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Continuation of schizophrenia treatment with three long-acting injectable antipsychotics in South Korea: A nationwide population-based study.
    Joo SW; Shon SH; Choi G; Koh M; Cho SW; Lee J
    Eur Neuropsychopharmacol; 2019 Sep; 29(9):1051-1060. PubMed ID: 31362852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rationale and neurobiological effects of treatment with antipsychotics in patients with chronic schizophrenia considering dopamine supersensitivity.
    Kimura H; Kanahara N; Iyo M
    Behav Brain Res; 2021 Apr; 403():113126. PubMed ID: 33460681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Indications for and use of long-acting injectable antipsychotics: consideration from an inpatient setting.
    Kishimoto T; Sanghani S; Russ MJ; Marsh AN; Morris J; Basu S; John M; Kane JM
    Int Clin Psychopharmacol; 2017 May; 32(3):161-168. PubMed ID: 28181959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clozapine use and sedentary lifestyle as determinants of metabolic syndrome in outpatients with schizophrenia.
    Eskelinen S; Sailas E; Joutsenniemi K; Holi M; Suvisaari J
    Nord J Psychiatry; 2015 Jul; 69(5):339-45. PubMed ID: 25981178
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patients With Early-Phase Schizophrenia Will Accept Treatment With Sustained-Release Medication (Long-Acting Injectable Antipsychotics): Results From the Recruitment Phase of the PRELAPSE Trial.
    Kane JM; Schooler NR; Marcy P; Achtyes ED; Correll CU; Robinson DG
    J Clin Psychiatry; 2019 Apr; 80(3):. PubMed ID: 31050233
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Attitudes of European physicians towards the use of long-acting injectable antipsychotics.
    Patel MX; Bent-Ennakhil N; Sapin C; di Nicola S; Loze JY; Nylander AG; Heres S
    BMC Psychiatry; 2020 Mar; 20(1):123. PubMed ID: 32169077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Schizophrenia, antipsychotics, and the metabolic syndrome: is there a silver lining?
    Remington G
    Am J Psychiatry; 2006 Jul; 163(7):1132-4. PubMed ID: 16816213
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.